Compare Amgen, Inc. (AMGN) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Nokia Corp — how do they compare? Amgen, Inc. trades at $417.82 (market cap $224.14B), while Nokia Corp trades at $10.39 (market cap $53.00B). The key difference: Amgen, Inc. is far larger — about 4.2× Nokia Corp's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | NOK | |
|---|---|---|
Market Cap | $224.14B | $53.00B |
Sector | Health | Technology |
52-Week High | $417.20 | $16.83 |
52-Week Low | $271.18 | $4.13 |
Enterprise Value | $267.45B | $50.95B |
Dividend Yield | 2.43% | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Nokia (NOK) trades at $9.12, down 2.67% today amid a bearish technical signal, with mixed earnings performance including a Q2 2026 EPS beat. Revenue has stabilized near $20B annually, but net margins are thin at 3.47%. The company is pivoting toward AI and cloud infrastructure, with recent news highlighting demand growth in these areas. Cash flow turned negative in 2025, though the balance sheet remains solid with $8.91B in cash.
Outlook is cautiously optimistic due to AI-driven demand and insider buying, but risks include telecom spending volatility and high P/E valuation. Analyst consensus is bullish with 60% buy ratings. The stock faces near-term pressure from technical indicators but offers long-term potential if AI initiatives accelerate growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
